Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This 52 week study will assess the use of intravitreal aflibercept injections in patients with neovascular glaucoma (NVG) compared to standard of care panretinal photocoagulation.

The investigators hypothesize that the neovascularization of the iris and angle present in neovascular glaucoma will resolve more quickly in eye treated with intravitreal aflibercept injection alone and result in increased comfort and preservation of visual field as compared to current standard of care utilizing pan-retinal photocoagulation. The advantages to intravitreal aflibercept injection use could include resolution of NVI/NVA (neovascularization of the iris/neovascularization of the angle) leading to quicker pain relief and quicker lowering of IOP (intraocular pressure).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• Patients with a diagnosis of neovascular glaucoma (Stage I-II)

• Individuals who are ages 21-90 years old; male or female of any race

• Presence of neovascularization of the iris and/or angle

• At least 90 degrees of "unzipped" anterior chamber angle as noted by gonioscopy. (a "zipped angle is the term used for a drainage angle that is slowly closing due to scar tissue from the neovascularization process)

• Visual acuity of light perception or better in the study eye

• Willing and able to comply with clinic visits and study-related procedures

• Provide signed informed consent

Exclusion Criteria:

• Use of intravitreal anti-VEGF agents in the study eye in the past 3 months.

• Full PRP in the study eye

• Prior vitrectomy in the study eye

• Prior trabeculectomy or other filtration surgery in the study eye

• Active ocular or periocular infection in the study eye

• Ocular conditions (Cataract or vitreous hemorrhage) that might require surgery in next 12 months

• Allergy to fluorescein dye

• Any past use of systemic anti-VEGF medication

• Myocardial infarction within 6 months prior to study enrollment

• Stroke within 6 months prior to study enrollment

• Pregnant or breast-feeding women

• Sexually active men or women of childbearing potential who are unwilling to practice adequate contraception during the study